[HTML] sciencedirect.com

[HTML][HTML] Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

CM Parseghian, JM Loree, VK Morris, X Liu… - Annals of …, 2019 - Elsevier
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …
被引用次数：205 相关文章

Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge

CM Parseghian, JM Loree, VK Morris, X Liu… - Annals of …, 2019 - profiles.wustl.edu
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

CM Parseghian, JM Loree, VK Morris, X Liu… - Annals of Oncology …, 2019 - europepmc.org
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

CM Parseghian, JM Loree, VK Morris… - Annals of oncology …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge

CM Parseghian, JM Loree… - Annals of …, 2019 - mdanderson.elsevierpure.com
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

CM Parseghian, JM Loree, VK Morris, X Liu… - Annals of …, 2019 - annalsofoncology.org
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …
[HTML] nih.gov

[HTML][HTML] Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

CM Parseghian, JM Loree, VK Morris, X Liu… - Annals of …, 2019 - ncbi.nlm.nih.gov
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge

CM Parseghian, JM Loree, VK Morris… - ANNALS OF …, 2019 - iris.unicampania.it
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …

[引用][C] Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge

CM Parseghian, JM Loree, VK Morris, X Liu… - Annals of …, 2019 - cir.nii.ac.jp
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR
re-challenge | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

CM Parseghian, JM Loree, VK Morris, X Liu… - Annals of Oncology …, 2019 - europepmc.org
Background Colorectal cancer (CRC) has been shown to acquire RAS and EGFR
ectodomain mutations as mechanisms of resistance to epidermal growth factor receptor …